FAQ
The litigation against Pfizer stemmed from claims that Bextra and Celebrex increased the risk and incidence of cardiovascular events in patients who were prescribed the medications primarily for arthritis-related pain. Seeger Weiss LLP, along with co-counsel, was one of the first firms to file Bextra and Celebrex related complaints against Pfizer in the United States and represented approximately 400 claimants. In 2005, Pfizer withdrew Bextra from the market, while Celebrex remained, but with a required Black Box safety warning regarding the risk of heart attacks and strokes.
The $894 million settlement was announced in 2008.